<DOC>
	<DOCNO>NCT01098734</DOCNO>
	<brief_summary>Welichem Biotech develop small molecule drug candidate , WBI-1001 , selectively target pathogenic feature inflammatory skin disease , include atopic dermatitis ( form eczema ) .The purpose clinical trial test safety efficacy WBI-1001 topically apply cream extend period 12 week patient mild moderate atopic dermatitis .</brief_summary>
	<brief_title>Non-steroid , Atopic Dermatitis Phase IIb 12-week Trial ; Topical WBI-1001 Cream</brief_title>
	<detailed_description>A multi-centered , double-blinded Phase IIb study evaluate safety efficacy non-steroid , anti-inflammatory WBI-1001 cream topical treatment patient mild moderate atopic dermatitis , express lesion 20 % BSA . For first 6 week patient randomize one three treatment group simultaneously ratio 1:1:1 . Group 1 : vehicle cream ( placebo ) , BID ; Group 2 : 0.5 % WBI-1001 cream , BID ; Group 3:1.0 % WBI-1001 cream , BID . Patients randomize treat lesion area . After first 6 week patient treat , non-placebo control , WBI-1001 cream . The Group 1 patient enter double-blinded phase 6 week half treat BID 0.5 % half 1.0 % WBI-1001 cream . Groups 2 3 continue treatment unchanged remain 6 week . During treatment period , patient apply cream ( BID ) kit provide , visit study centre prescribe time assessment efficacy , safety tolerability . After completion 12-week treatment period patient 2-week follow-up visit . Patients withdraw study Day 42 reason treatment relate AE replace least 40 patient per group complete placebo-controlled phase .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Clinical diagnosis chronic atopic dermatitis ( Hanifin 's criterion ) great 6 month minimum 5 % maximum 20 % BSA . IGA score 24 Day 0 . WOCBP must negative serum betahCG pregnancy test randomization , male partner must take pregnancy precaution duration study , also must male patient . Willing comply Protocol attend visit . Provide write informed consent prior enter study procedure . Patient latent active tuberculosis infection accord medical history current examination test . Pregnancy lactation . Spontaneously improve rapidly deteriorate atopic dermatitis . Presence atopic dermatitis hand and/or foot . Any skin disease atopic dermatitis might interfere clinical assessment put patient risk . Active allergic contact dermatitis nonatopic form atopic dermatitis . Other concommitant serious illness medical condition , virus renal insufficiency , clinically significant abnormality could put patient risk study . History neurological/psychiatric disorder include psychotic disorder , dementia reason would interfere patient 's participation . Systemic immunomodulatory therapy condition within 4 week prior baseline visit . Any phototherapy , photochemotherapy systemic atopic dermatitis therapy within 2 week baseline visit . Prolonged exposure natural artificial source UV within 4 week prior baseline visit intention exposure study . Topical atopic dermatitis therapy ( include corticosteroid calcineurins ) area treat within 2 week prior baseline . Alcohol abuse last 2 year . Allergic history nonmedical ingredient study cream . Treatment investigational drug within one month Day 0 current participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>non-steroid</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>skin disease</keyword>
	<keyword>topical cream</keyword>
	<keyword>small molecule</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>eczema</keyword>
</DOC>